Quantities
| P4250 | defined daily dose | 0.1 |
| P1552 | has characteristic | ... | Q679692 (biopharmaceutical) | biopharmaceutical |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P2175 | medical condition treated | ... | Q220570 (pulmonary embolism) | pulmonary embolism |
| P2175 | medical condition treated | ... | Q1209150 (cerebral infarction) | cerebral infarction |
| P2175 | medical condition treated | ... | Q18553787 (cerebral artery occlusion) | cerebral artery occlusion |
| P2175 | medical condition treated | ... | Q18558122 (acute myocardial infarction) | acute myocardial infarction |
| P769 | significant drug interaction | ... | Q190016 (heparin) | heparin |
| P769 | significant drug interaction | ... | Q18216 (aspirin) | aspirin |
| P769 | significant drug interaction | ... | Q304088 (acenocoumarol) | acenocoumarol |
| P769 | significant drug interaction | ... | Q307088 (abciximab) | abciximab |
| P769 | significant drug interaction | ... | Q410237 (clopidogrel) | clopidogrel |
| P769 | significant drug interaction | ... | Q414462 (apixaban) | apixaban |
| P769 | significant drug interaction | ... | Q1640947 (phenindione) | phenindione |
| P769 | significant drug interaction | ... | Q1851701 (dalteparin) | dalteparin |
| P769 | significant drug interaction | ... | Q420542 (ticagrelor) | ticagrelor |
| P769 | significant drug interaction | ... | Q2295855 (eptifibatide) | eptifibatide |
| P769 | significant drug interaction | ... | Q20817252 (tinzaparin) | tinzaparin |
| P769 | significant drug interaction | ... | Q27077698 (fondaparinux) | fondaparinux |
| P769 | significant drug interaction | ... | Q105969996 (enoxaparin) | enoxaparin |
| P769 | significant drug interaction | ... | Q415366 (tirofiban) | tirofiban |
| P769 | significant drug interaction | ... | Q416232 (prasugrel) | prasugrel |
| P769 | significant drug interaction | ... | Q420262 (rivaroxaban) | rivaroxaban |
| P769 | significant drug interaction | ... | Q113368879 (rac-warfarin) | rac-warfarin |
| P279 | subclass of | ... | Q95349913 (antithrombotic enzyme) | antithrombotic enzyme |
| P2868 | subject has role | ... | Q35456 (essential medicine) | essential medicine |
| P2868 | subject has role | ... | Q13581432 (plasminogen activator) | plasminogen activator |
| P267 | ATC code | B01AD02 |
| P267 | ATC code | S01XA13 |
| P231 | CAS Registry Number | 105857-23-6 |
| P592 | ChEMBL ID | CHEMBL1201593 |
| P715 | DrugBank ID | DB00009 |
| P9635 | electronic Essential Medicines List medicine ID | 482 |
| P2671 | Google Knowledge Graph ID | /g/1229dx6j |
| P665 | KEGG ID | D02837 |
| P2115 | NDF-RT ID | N0000147695 |
| P7775 | RationalWiki ID | Activase |
| P3345 | RxNorm CUI | 8410 |
| P5082 | Store medisinske leksikon ID | alteplase |
| P652 | UNII | 1RXS4UE564 |
| P11143 | WikiProjectMed ID | Alteplase |
Why not click here or view trends?
log id: 2008554